

# InSphero AG and Cosmo Bio Co., Ltd Enter into Partnership to Distribute InSphero's Innovative Product Portfolio in Japan

---

*InSphero AG and Cosmo Bio Co., Ltd Enter into Strategic Partnership to Distribute InSphero's Innovative Product Portfolio in Japan*

ZURICH, ZURICH, SWITZERLAND, August 2, 2023 /EINPresswire.com/ -- [InSphero AG](#) and [Cosmo Bio Co., Ltd.](#) are announcing a strategic partnership to distribute InSphero's innovative product portfolio in Japan. This alliance, effective immediately, will see Cosmo Bio becoming the exclusive distributor of InSphero's 3D cell-based assay solutions across the Japanese market.

InSphero, a global pioneer in 3D cell culture and organ-on-chip technology, is known for its advanced 3D microtissues and assay services. It is widely employed by pharmaceutical, chemical, and cosmetic industries for more accurate, cost-effective testing of new substances and ingredients.

With its vast network and experience in life science product distribution, Cosmo Bio will allow the Swiss biotech company to deepen its footprint in the vital Japanese market.

Paul Cl  men  on, Head of Business Development at InSphero, says: "We are thrilled about our partnership with Cosmo Bio. Their reputation as a leading supplier of life sciences reagents and instruments in Japan is impeccable. We firmly believe this collaboration will significantly boost the availability and adoption of our innovative 3D cell-based assay solutions in Japan. It's a momentous day for us at InSphero as we continue to scale our international operations."

The Cosmo Bio team echoes this excitement. Haruhisa Sakurai, Ph.D., CEO and President of Cosmo Bio, remarks: "InSphero's products embody a leap forward in biotechnology. We are eager to distribute their leading-edge 3D cell culture technology to our customers. It is a privilege to partner with a company that shares our commitment to scientific innovation and customer satisfaction."

Both companies anticipate that this partnership will significantly benefit researchers and enterprises in Japan, enabling them to access world-class 3D microtissue models for drug development, safety testing, and disease modeling.

## About Cosmo Bio

Cosmo Bio is an organization established to sell and distribute biological reagents and services for the biotechnology market including biopharmaceutical applications studies, headquartered in Tokyo, with a network of over 200 contracted dealers throughout Japan. Cosmo Bio is one of the largest and most established life sciences reagents and services suppliers in Japan.

## About InSphero

InSphero is the only 3D in vitro model company with the platform and expertise to modernize drug discovery in a way that empowers researchers to reach their full potential. Our innovative spheroid-based models allow more effective, safe therapies to contact the clinic through superior robustness, reliability, reproducibility, and scalability. InSphero's goal is to inspire the next generation of breakthrough therapies through customer obsession, commitment to innovation, and the model of excellence.

Learn more at [insphero.com](https://insphero.com). Follow the company on LinkedIn and sign up for the Scientific Newsletter.

## Media Contacts

### Cosmo Bio

Norihiko Shibayama

[ir-contact@cosmobio.co.jp](mailto:ir-contact@cosmobio.co.jp)

### Paul Cl  men  on

InSphero

+41 44 515 04 90

[paul.clemencon@insphero.com](mailto:paul.clemencon@insphero.com)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/647313644>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

   1995-2023 Newsmatics Inc. All Right Reserved.